Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension
<b>Background:</b> Pulmonary hypertension (PH) is a common comorbidity in infants with bronchopulmonary dysplasia (BPD). Sildenafil is a widely recognized therapy for PH, but its efficacy in infants with BPD is questionable. We propose to assess the efficacy of sildenafil in BPD-associat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/10/8/1397 |
| _version_ | 1797585143581376512 |
|---|---|
| author | Kacie Dillon Vineet Lamba Ranjit R. Philip Mark F. Weems Ajay J. Talati |
| author_facet | Kacie Dillon Vineet Lamba Ranjit R. Philip Mark F. Weems Ajay J. Talati |
| author_sort | Kacie Dillon |
| collection | DOAJ |
| description | <b>Background:</b> Pulmonary hypertension (PH) is a common comorbidity in infants with bronchopulmonary dysplasia (BPD). Sildenafil is a widely recognized therapy for PH, but its efficacy in infants with BPD is questionable. We propose to assess the efficacy of sildenafil in BPD-associated PH as evaluated based on transthoracic echocardiography (TTE) changes and clinical measures. <b>Methods:</b> Data were retrospectively and prospectively collected. Inclusion criteria were gestational age (GA) < 32 weeks, birth weight (BW) < 1500 g with severe BPD, diagnosis of PH via TTE on sildenafil treatment. PH was evaluated via TTE, which was performed monthly after 36 weeks post-menstrual age (PMA) as a standard of care, and re-reviewed by a single pediatric cardiologist, who was blind to the initial reading. <b>Results:</b> In total, 19 patients were enrolled in the study, having a median GA of 24 3/7 weeks (IQR 23 5/7–25 5/7) and a median BW of 598 g (IQR 572–735). Sildenafil treatment was started at a median PMA of 40.4 weeks. The median respiratory severity score (RSS) at 28 d was 6.5, RSS and FiO2 showed improvement about 12 weeks after starting sildenafil treatment. <b>Conclusions:</b> Improvement in PH was noted via TTE, and patients had improvement in their RSS and FiO2 after prolonged therapy. However, TTE improvements did not correlate with clinical improvements. |
| first_indexed | 2024-03-11T00:02:50Z |
| format | Article |
| id | doaj.art-dc8e469e314a41a5a1108cac18ca9221 |
| institution | Directory Open Access Journal |
| issn | 2227-9067 |
| language | English |
| last_indexed | 2024-03-11T00:02:50Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Children |
| spelling | doaj.art-dc8e469e314a41a5a1108cac18ca92212023-11-19T00:40:59ZengMDPI AGChildren2227-90672023-08-01108139710.3390/children10081397Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary HypertensionKacie Dillon0Vineet Lamba1Ranjit R. Philip2Mark F. Weems3Ajay J. Talati4Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38163, USADivision of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38163, USADivision of Pediatric Cardiology, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38163, USADivision of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38163, USADivision of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38163, USA<b>Background:</b> Pulmonary hypertension (PH) is a common comorbidity in infants with bronchopulmonary dysplasia (BPD). Sildenafil is a widely recognized therapy for PH, but its efficacy in infants with BPD is questionable. We propose to assess the efficacy of sildenafil in BPD-associated PH as evaluated based on transthoracic echocardiography (TTE) changes and clinical measures. <b>Methods:</b> Data were retrospectively and prospectively collected. Inclusion criteria were gestational age (GA) < 32 weeks, birth weight (BW) < 1500 g with severe BPD, diagnosis of PH via TTE on sildenafil treatment. PH was evaluated via TTE, which was performed monthly after 36 weeks post-menstrual age (PMA) as a standard of care, and re-reviewed by a single pediatric cardiologist, who was blind to the initial reading. <b>Results:</b> In total, 19 patients were enrolled in the study, having a median GA of 24 3/7 weeks (IQR 23 5/7–25 5/7) and a median BW of 598 g (IQR 572–735). Sildenafil treatment was started at a median PMA of 40.4 weeks. The median respiratory severity score (RSS) at 28 d was 6.5, RSS and FiO2 showed improvement about 12 weeks after starting sildenafil treatment. <b>Conclusions:</b> Improvement in PH was noted via TTE, and patients had improvement in their RSS and FiO2 after prolonged therapy. However, TTE improvements did not correlate with clinical improvements.https://www.mdpi.com/2227-9067/10/8/1397bronchopulmonary dysplasiaBPDpulmonary hypertensionsildenafil |
| spellingShingle | Kacie Dillon Vineet Lamba Ranjit R. Philip Mark F. Weems Ajay J. Talati Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension Children bronchopulmonary dysplasia BPD pulmonary hypertension sildenafil |
| title | Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension |
| title_full | Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension |
| title_fullStr | Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension |
| title_full_unstemmed | Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension |
| title_short | Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension |
| title_sort | efficacy of sildenafil in infants with bronchopulmonary dysplasia associated pulmonary hypertension |
| topic | bronchopulmonary dysplasia BPD pulmonary hypertension sildenafil |
| url | https://www.mdpi.com/2227-9067/10/8/1397 |
| work_keys_str_mv | AT kaciedillon efficacyofsildenafilininfantswithbronchopulmonarydysplasiaassociatedpulmonaryhypertension AT vineetlamba efficacyofsildenafilininfantswithbronchopulmonarydysplasiaassociatedpulmonaryhypertension AT ranjitrphilip efficacyofsildenafilininfantswithbronchopulmonarydysplasiaassociatedpulmonaryhypertension AT markfweems efficacyofsildenafilininfantswithbronchopulmonarydysplasiaassociatedpulmonaryhypertension AT ajayjtalati efficacyofsildenafilininfantswithbronchopulmonarydysplasiaassociatedpulmonaryhypertension |